Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,124 | 165 | 941 |
| Samples | 875 | 134 | 729 |
| Peptides | 650 | 91 | 572 |
Function
PDGFRA · Platelet derived growth factor receptor alpha
This gene encodes a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family. These growth factors are mitogens for cells of mesenchymal origin. The identity of the growth factor bound to a receptor monomer determines whether the functional receptor is a homodimer or a heterodimer, composed of both platelet-derived growth factor receptor alpha and beta polypeptides. Studies suggest that this gene plays a role in organ development, wound healing, and tumor progression. Mutations in this gene have been associated with idiopathic hypereosinophilic syndrome, somatic and familial gastrointestinal stromal tumors, and a variety of other cancers. [provided by RefSeq, Mar 2012].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 646 amino-acid changes on canonical ENST00000257290 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PDGFRA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PDGFRA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 18/133 14% |
| Endometrial Carcinoma | 5/42 12% | 37/612 6% |
| Non-Small Cell Lung Carcinoma | 27/304 9% | 61/1390 4% |
| Unknown | 1/10 10% | 1/29 3% |
| Melanoma | 14/210 7% | 92/1899 5% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 33/810 4% |
| Other Solid Cancers | 9/94 10% | 50/1515 3% |
| Small Cell Lung Carcinoma | 0/9 0% | 25/752 3% |
| Colorectal Carcinoma | 14/143 10% | 95/3239 3% |
| Neuroendocrine Tumour | 18/154 12% | 5/577 1% |
| Glioma | 0/52 0% | 64/2127 3% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Bladder Carcinoma | 2/58 3% | 20/956 2% |
| Gastric Carcinoma | 0/74 0% | 40/1809 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Ovarian Carcinoma | 5/109 5% | 12/998 1% |
| Cervical Carcinoma | 0/35 0% | 7/422 2% |
| Hepatocellular Carcinoma | 0/46 0% | 29/2210 1% |
| Biliary Tract Carcinoma | 3/54 6% | 9/950 1% |
| Breast Carcinoma | 8/144 6% | 32/3264 1% |
| Plasma Cell Myeloma | 0/44 0% | 4/305 1% |
| Chondrosarcoma | 1/14 7% | 0/75 0% |
| Esophageal Carcinoma | 0/23 0% | 8/769 1% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| Head and Neck Carcinoma | 0/85 0% | 15/1574 1% |
| Medulloblastoma | 0/0 0% | 4/450 1% |
| Mesothelioma | 0/62 0% | 2/165 1% |
| Non-Cancerous | 1/104 1% | 7/830 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 15/2550 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
Mutation Distribution
Where PDGFRA is mutated · all tissues, split by cell line vs tissue
How many mutations in PDGFRA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,124 mutations in PDGFRA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|